Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
America’s dependence on foreign generic manufacturing is a real national security and supply concern. The vast majority of drug shortages in the U.S. are generics and shortages have increasingly burdened pharmacies across the country and disrupted care for the patients who rely on them, particularly those with chronic pain and cancer.
But President Trump’s most recent policy is unlikely to fix that problem. It’s far more likely to make American medicine cabinets less reliable, not more.